Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...

The 69-year-old actor opened up about his harrowing experience which took place during the pandemic on Joe Rogan's podcast.

Seasoned advisory group including RNA, translation and commercialisation luminaries.

The president-elect might bring back efforts to make other countries pay more for drugs, but there are pitfalls.

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for ...

The diagnosed prevalent cases of HIV are projected to increase globally at an annual growth rate of 0.90 pc from 2.00 million ...

Gilead Sciences (GILD) ended the recent trading session at $89.14, demonstrating a -1.64% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of ...

Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

This was the stock's fifth consecutive day of losses.

The changes will result in one company focused exclusively on cancer cell therapies and another on strategic transactions to build a pipeline of innovative medicines.